EP2124629A1 - Flavouring composition - Google Patents
Flavouring compositionInfo
- Publication number
- EP2124629A1 EP2124629A1 EP08709312A EP08709312A EP2124629A1 EP 2124629 A1 EP2124629 A1 EP 2124629A1 EP 08709312 A EP08709312 A EP 08709312A EP 08709312 A EP08709312 A EP 08709312A EP 2124629 A1 EP2124629 A1 EP 2124629A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- flavonoids
- powder
- food
- ppw
- mustard
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 229930003935 flavonoid Natural products 0.000 claims abstract description 134
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 134
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 132
- 239000000843 powder Substances 0.000 claims abstract description 76
- 235000013305 food Nutrition 0.000 claims abstract description 56
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 51
- 244000269722 Thea sinensis Species 0.000 claims abstract description 51
- 235000003351 Brassica cretica Nutrition 0.000 claims abstract description 37
- 235000003343 Brassica rupestris Nutrition 0.000 claims abstract description 37
- 235000010460 mustard Nutrition 0.000 claims abstract description 37
- 241000219198 Brassica Species 0.000 claims abstract description 36
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000019658 bitter taste Nutrition 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000000796 flavoring agent Substances 0.000 claims abstract description 13
- 235000019634 flavors Nutrition 0.000 claims abstract description 12
- 235000013373 food additive Nutrition 0.000 claims abstract description 12
- 239000002778 food additive Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 235000019508 mustard seed Nutrition 0.000 claims abstract description 8
- 235000015097 nutrients Nutrition 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 230000037396 body weight Effects 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 239000002537 cosmetic Substances 0.000 claims abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 42
- 235000011430 Malus pumila Nutrition 0.000 claims description 29
- 235000015103 Malus silvestris Nutrition 0.000 claims description 29
- 235000013616 tea Nutrition 0.000 claims description 29
- 241000220225 Malus Species 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 230000003647 oxidation Effects 0.000 claims description 19
- 238000007254 oxidation reaction Methods 0.000 claims description 19
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 18
- 239000011591 potassium Substances 0.000 claims description 18
- 229910052700 potassium Inorganic materials 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 16
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 235000019640 taste Nutrition 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 235000002378 plant sterols Nutrition 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 235000013310 margarine Nutrition 0.000 claims description 3
- 239000003264 margarine Substances 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000006558 Dental Calculus Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 102000011990 Sirtuin Human genes 0.000 claims description 2
- 108050002485 Sirtuin Proteins 0.000 claims description 2
- 206010044029 Tooth deposit Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000002925 dental caries Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 241000234282 Allium Species 0.000 claims 7
- 235000019198 oils Nutrition 0.000 claims 1
- 244000291564 Allium cepa Species 0.000 abstract description 45
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 26
- 235000011194 food seasoning agent Nutrition 0.000 description 21
- 235000009569 green tea Nutrition 0.000 description 15
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 13
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 13
- 230000003078 antioxidant effect Effects 0.000 description 13
- 235000005875 quercetin Nutrition 0.000 description 13
- 229960001285 quercetin Drugs 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 12
- 244000081841 Malus domestica Species 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 10
- 235000005487 catechin Nutrition 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 9
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 238000010411 cooking Methods 0.000 description 9
- 229930000223 plant secondary metabolite Natural products 0.000 description 9
- 150000001765 catechin Chemical class 0.000 description 8
- 235000017807 phytochemicals Nutrition 0.000 description 8
- 235000013599 spices Nutrition 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000012734 epicatechin Nutrition 0.000 description 7
- 229940030275 epigallocatechin gallate Drugs 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 235000012055 fruits and vegetables Nutrition 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 235000013311 vegetables Nutrition 0.000 description 7
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 6
- 235000021016 apples Nutrition 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 6
- -1 flavonoid compounds Chemical class 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 206010025476 Malabsorption Diseases 0.000 description 5
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940094952 green tea extract Drugs 0.000 description 5
- 235000020688 green tea extract Nutrition 0.000 description 5
- 230000007407 health benefit Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 244000178993 Brassica juncea Species 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 244000061456 Solanum tuberosum Species 0.000 description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 235000015598 salt intake Nutrition 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 244000140786 Brassica hirta Species 0.000 description 3
- 235000011371 Brassica hirta Nutrition 0.000 description 3
- 241000219193 Brassicaceae Species 0.000 description 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 201000011529 cardiovascular cancer Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 235000015504 ready meals Nutrition 0.000 description 3
- 235000020095 red wine Nutrition 0.000 description 3
- 235000019643 salty taste Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 235000011332 Brassica juncea Nutrition 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000015241 bacon Nutrition 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005189 cardiac health Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000019221 dark chocolate Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- MYMGKIQXYXSRIJ-UHFFFAOYSA-N rhamnacene Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 MYMGKIQXYXSRIJ-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- SAZHWFFOFMSQPA-UHFFFAOYSA-N 4-phenylcoumarin Chemical compound C12=CC=CC=C2OC(=O)C=C1C1=CC=CC=C1 SAZHWFFOFMSQPA-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 235000006463 Brassica alba Nutrition 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000014700 Brassica juncea var napiformis Nutrition 0.000 description 1
- 235000005855 Brassica juncea var. subintegrifolia Nutrition 0.000 description 1
- 244000180419 Brassica nigra Species 0.000 description 1
- 235000011291 Brassica nigra Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical group OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 241000427324 Glinus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 241000366676 Justicia pectoralis Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N flavanone Chemical group O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 229930014802 neoflavonoid Natural products 0.000 description 1
- 150000002804 neoflavonoids Chemical class 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- KQFUXLQBMQGNRT-UHFFFAOYSA-N pachypodol Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 KQFUXLQBMQGNRT-UHFFFAOYSA-N 0.000 description 1
- UOJMTSCORVQOHS-UHFFFAOYSA-N pachypodol Natural products COc1cc(ccc1O)C2=C(C)C(=O)c3c(O)cc(C)cc3O2 UOJMTSCORVQOHS-UHFFFAOYSA-N 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- QULMBDNPZCFSPR-UHFFFAOYSA-N petunidin chloride Chemical compound [Cl-].OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 QULMBDNPZCFSPR-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 238000009138 potassium supplementation Methods 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 235000008603 tangeritin Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BPJYAXCTOHRFDQ-UHFFFAOYSA-L tetracopper;2,4,6-trioxido-1,3,5,2,4,6-trioxatriarsinane;diacetate Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].CC([O-])=O.CC([O-])=O.[O-][As]1O[As]([O-])O[As]([O-])O1.[O-][As]1O[As]([O-])O[As]([O-])O1 BPJYAXCTOHRFDQ-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/105—Natural spices, flavouring agents or condiments; Extracts thereof obtained from liliaceae, e.g. onions, garlic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/18—Mustard
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/86—Addition of bitterness inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the use of flavonoids as flavouring substances and/or as salt substitutes, to a composition containing flavonoids as well as to a process for the production of said flavonoid composition.
- a flavonoid powder preparation according to the present invention is especially well suited to be used as a general flavouring substance.
- the flavonoid composition according to the invention is suitable for replacing table salt totally or in part in household cooking as well as in food industry.
- Especially the present invention concerns the use of mustard powder for preventing the bitter taste of flavonoids.
- Flavonoids are one of the widest found groups of vegetable chemical compounds. They are polyphenols antioxidants naturally present in vegetables, fruits, and beverages. Good sources of flavonoids include all citrus fruits, berries, onions, parsley, legumes, green tea, red wine, seabuckthorn, and dark chocolate (that with a cocoa content of seventy percent or greater). Antioxidants help protect our cells from damage caused by free radicals and may fight off several diseases such as cancer, heart disease, inflammation and neurodegenerative diseases such as Parkinson's and Alzheimer's.
- flavonoid refers to a class of plant secondary metabolites. According to the IUPAC nomenclature, they can be classified into:
- flavonoids derived from the 2-phenylchromone (2-phenyl-l,4- benzopyrone) structure
- isoflavonoids derived from the 3-phenylchromone (3-phenyl-l,4- benzopyrone) structure
- isoflavonoids derived from the 3-phenylchromone (3-phenyl-l,4- benzopyrone) structure
- neoflavonoids derived from the 4-phenylcoumarine (4-phenyl-l,2- benzopyrone) structure.
- Isoflavone phytoestrogens from soy could be the most researched phytochemical in the world, with hundreds of published studies to date. Dozens of studies in the 1990s alone focused on the possible easing of menopause symptoms. Moreover, soy isoflavones are being examined for possible benefits to: heart health, cancer, PMS, osteoporosis, improved cognition, protection from UV damage and aging, and even improved sleep. Over 5000 naturally occurring flavonoids have been characterized from various plants. They have been classified according to their chemical structure, and are usually subdivided into 6 subgroups:
- Flavones use the 2-phenyl-4H-l-benzopyran-4-one skeleton (Examples: Luteolin, Apigenin, Tangeritin) ;
- Flavonols use the 3-hydroxy-2-phenyl-4H-l-benzopyran-4-one skeleton (Examples: Quercetin, Kaempferol, Myricetin, Isorhamnetin, Pachypodol, Rhamnazin);
- Flavanones use the 2,3-dihydro-2-phenyl-4H-l-benzopyran-4-one skeleton (Examples: Hesperetin, Naringenin, Eriodictyol);
- Flavan-3-ols use the 2,3-dihydro-3-hydroxy-2-phenyl-benzopyran skeleton (Examples: Catechins (Catechin (C), Gallocatechin (GC), Catechin 3-gallate (Cg), Gallocatechin 3-gallate (GCg)), Epicatechins (Epicatechin (EC), Epigallocatechin (EGC), Epicatechin 3-gallate (ECg), Epigallocatechin 3- gallate (EGCg)));
- Isoflavones use the 3-phenyl-4H-l-benzopyran-4-one skeleton (Examples: Genistein, Daidzein, Glycitein);
- Flavonoids are most commonly known for their antioxidant activity. Flavonoids are also commonly referred to as bioflavonoids. These terms are equivalent and interchangeable, since all flavonoids are biological in origin. Flavonoids have been referred to as "nature's biological response modifiers" because of strong experimental evidence of their inherent ability to modify the body's reaction to allergens, viruses, and carcinogens. They show anti-allergic, anti-inflammatory, anti-microbial and anti-cancer activity. In addition, flavonoids act as powerful antioxidants, protecting against oxidative and free radical damage.
- Oxidation of low density lipoproteins by free radicals is thought to play a central part in the development of atherosclerosis. Antioxidants may thus delay the onset of atherogenesis.
- Several flavonoid compounds have been shown to have antioxidant properties in vitro, inhibiting the oxidation of low density lipoproteins and reducing thrombotic tendencies by inhibiting platelet aggregation.
- the major flavonoids in onion are two quercetin glycosides, quercetin 4'-O-beta- glucoside (Q4'G) and quercetin 3,4'-O-beta-diglucosides (Q3,4'G), which are recognized as bioactive substances that are good for our health.
- Quercetin is a flavonoid and more specifically a flavonol that constitutes the aglycone of the glycoside rutin. Quercetin has been found to be the most active of the flavonoids, and many medicinal plants owe much of their activity to their high quercetin content. Quercetin has demonstrated significant anti-inflammatory activity because of direct inhibition of several initial processes of inflammation. For example, it inhibits both the production and release of histamine and other allergic/inflammatory mediators. In addition, it exerts potent antioxidant activity and vitamin C-sparing action.
- Green tea flavonoids are potent antioxidant compounds, thought to reduce incidence of cancer and heart disease.
- the major flavonoids in green tea are the catechins (catechin, epicatechin, epicatechin gallate, and epigallocatechin gallate(EGCG)).
- EGCG epigallocatechin gallate
- the leaves are allowed to oxidize, during which enzymes present in the tea convert some or all of the catechins to larger molecules.
- green tea is produced by steaming the fresh-cut leaf, which inactivates these enzymes, and oxidation does not significantly occur.
- green tea has also been shown to lower blood sugar and cholesterol and even promote weight loss; increasing energy and thermogenesis and retarding adipose (fat) cell growth and fat absorption in the intestine. It has also been suggested that it is good to preserve the profile of the catechins naturally in green tea, because there are chemicals in tea that are complimentary and create a synergistic effect.
- Epicatechin improves blood flow and thus seems good for cardiac health. Cocoa, the major ingredient of dark chocolate, contains relatively high amounts of epicatechin and has been found to have nearly twice the antioxidant content of red wine and up to three times that of green tea. However, green tea remains as an important source of epicatechin.
- Proanthocyanidins extracts demonstrate a wide range of pharmacological activity. Their effects include increasing intracellular vitamin C levels, decreasing capillary permeability and fragility, scavenging oxidants and free radicals, and inhibiting destruction of collagen, the most abundant protein in the body.
- CN 1093546 discloses a flavonoid food additive.
- KR 9404838 discloses extraction of the green tea flavonoid.
- WO 96/33728 discloses a Ginkgo biloba leaf flavonoid extract which can be used as a flavouring ingredient.
- EP 0 766 927 discloses a salt mixture poor in sodium, comprising also potassium and magnesium and a mixture of vegetables and spices. However, no flavonoids are mentioned in the patent.
- WO 98/18348 discloses the use of flavonoids as flavouring substances and/or as salt substitutes.
- flavonoids such as from onion, apple and tea are mixed to form a composition.
- the flavonoid preparation is used as a general flavouring substance and as a salt substitute.
- the presence of flavonoids in citrus and other fruits often carries an offensive bitterness.
- the problem with known flavouring substances containing flavonoids is the same bitter taste. The problem is often even worse when typical sodium chloride substitutes containing magnesium and potassium are used. Magnesium and potassium are known to possess an offensive bitter taste.
- WOF WOF
- WOF is described as bitter or metallic and is due primarily to oxidation of unsaturated fatty acids from the disrupted muscle tissue cell membranes (oxidised iron from myoglobin and haemoglobin may also play a role).
- An object of the present invention is thus to overcome the problems of the known salt substitutes and flavonoid compositions.
- the objects of the invention are achieved by a flavouring composition, a method and uses which are characterized by what is stated in the independent claims.
- the preferred embodiments of the invention are disclosed in the dependent claims.
- the present invention is based on the realization that specific combination of flavonoids may be extracted and/or powdered and made into a flavouring substance, a spice or food additive, which may be used as a general seasoning on or in food.
- the synergistic effect of these flavonoids has proved to impact positively to human health. Further, the offensive bitterness of flavonoids is overcome by the addition mustard to the composition.
- An advantage of the invention is the possibility to achieve multiple effects by the addition of just one component to the composition.
- Mustard powder provides better taste, by preventing the bitter taste of flavonoids and also preventing the bitter taste of potassium and magnesium. Further, the Mustard it self has antioxidant activity and pharmacological effects on cardiovascular disease, cancer, and diabetes, which provides synergistic effects with the other antioxidants of the composition.
- the function of the flavoring compositions containing flavonoids in human body is illustrated in the Figure 1.
- the present invention is directed to a flavouring composition containing flavonoids of onion, tea, and/or apple, wherein the composition further contains contains flavor of mustard seeds, preferably powder and/or extract of mustard.
- mustard belongs to the family of Brassicaceae and it is the seeds of the mustard that are used as a spice.
- the different mustards include Sinapis alba L. (white or yellow mustard), Brassica nigra L. Koch (black or true mustard), Brassica juncea L. Czern. et Cosson (oriental, leaf, or Indian mustard).
- the genus Brassica contains over 150 species that are cultivated worldwide as oilseed crops or vegetables.
- Ground mustard, derived from the powdered mustard seed, is commonly known as mustard flour, but is also called mustard powder.
- the main types of mustard seed consist of single or mixed white, black, or brown seed. More pungent mustards are derived from seeds from which the fixed oil has been removed.
- Mustard also has antioxidant activity and pharmacological effects on cardiovascular disease, cancer, and diabetes.
- the flavouring composition contains a mixture of at least three flavonoids, wherein said flavonoids are selected from flavonoids contained in onion, tea, and/or apple.
- the composition of the invention contains powder and/or extract of onion, tea and apple.
- a flavouring composition contains also an edible carrier such as sodium chloride (NaCI), potassium chloride (KCI), calcium chloride (CaCI 2 ), magnesium chloride (MgCI 2 ) and/or mixtures thereof.
- the amount of an edible carrier can be up to 80 %, preferably up to 50 % and more preferably up to 30 % by weight of the total composition.
- the flavonoid composition of the present invention contains a combination of several, preferably at least three flavonoids, which are preferably selected so as to provide a salty taste.
- a preferred embodiment comprises a flavouring substance which may be used to substitute table salt.
- Suitable anti-caking agents are Silicon Dioxide (E 551) and tetra calcium pyrophosphate.
- the invention also relates to a process for the preparation of a flavouring composition, wherein powder and/or extract of onion, tea, apple and mustard are mixed, optionally with an edible carrier, to provide a flavouring composition.
- the components of said composition include flavonoids which provide the taste of salt and make said composition useful as a substitute for table salt in foods.
- the invention provides the use of the flavour of mustard seeds, preferably mustard powder or extract, for altering or preventing the bitter taste of flavonoids.
- the flavonoids can be contained in a medicament, a nutrient, a drink, a food or a food additive and the use of mustard powder is especially effective when the bitter taste is caused by flavonoids of onion, tea and apple. Therefore in an embodiment the invention provides the use of mustard powder for preventing the bitter taste of an edible product containing onion powder, tea powder and apple powder.
- mustard powder is also effective for altering or preventing the bitter taste of the edible product is at least partly caused by potassium and/or magnesium.
- the invention provides also a method for preventing the bitter taste of a medicament, a nutrient, a drink, a food or a food additive, wherein the bitter taste is caused by flavonoids.
- the method being characterized in that the method comprises adding of mustard powder to said food or food additive.
- the composition of the invention is used as a medicament.
- the composition of the invention can be used in the manufacture of a medicament, a nutrient, a drink, a food additive or a food product for the treatment of cardiovascular diseases, hypertension (high blood pressure), high cholesterol, arteriosclerosis, obesity, dental calculus, caries, diarrhea, flu, influenza, DNA oxidation, diabetes, arthritis (reduces collagen infection, inflammation), cancer or asthma, or for regulating sirtuin activity.
- the present invention provides also the use of a flavoring composition containing flavonoids for the cosmetic treatment of a mammal to cause loss of body weight.
- the present invention provides a solution to the above problem by using flavonoids together with plant sterols and stanols.
- flavonoids alleviates the oxidation problem. Flavonoids are antioxidant and they prevent the unwanted oxidation of plant sterols and stanols during heating. This gives the possibility to develop totally new range of functional food products.
- the invention also provides a food product containing a plant strerol or a stanol, preferably a plant sterol, and the flavouring composition of the invention.
- a food product containing a plant strerol or a stanol, preferably a plant sterol, and the flavouring composition of the invention.
- examples of such food products are margarine, butter and vegetable oil.
- flavouring composition of the invention for preserving food.
- the flavouring composition is especially suitable for preserving food that is frozen after addition of the flavouring composition.
- the use of the flavouring composition of the invention for preserving food that is heated above 50 °C before serving is advantageous because then also the undesired WOF effect can be avoided.
- An object of the invention is thus to provide a functional spice based on flavonoids. Another object of the invention is to provide a seasoning having an inherent taste of salt. A further object of the invention is to provide a substitute for table salt in the food industry, in restaurants as well as in household cooking. An object of the invention is also to provide a salt substitute for ready-made foods, bakery products, snacks, etc. A further object of the invention is to provide an easy way of adding health bringing flavonoids to the normal diet of a person.
- Another object of the invention is to provide a seasoning having antioxidant properties in vitro and in vivo and being capable of inhibiting the oxidation of low density lipoproteins and of reducing thrombotic tendencies by inhibiting platelet aggregation.
- flavonoid flavouring substance according to the present invention will have the dual benefit of providing a good aromatic taste to the food and of supplementing the person's normal diet with healthy flavonoids without requiring him or her to drink a lot of wine or eat a lot of onions or apples.
- the present flavonoid composition provides for the first time a realistic way of reducing the amount of salt in the diet to an acceptable level while retaining the taste of salt in the food at an accustomed level. It is an accepted fact that reducing the salt intake to about 25% of the present normal level significantly reduces the risk for fatal coronary diseases.
- a regular and continuous intake of flavonoids as such also has the effect of reducing the risk for coronary diseases.
- a dual benefit is obtained by the present invention in both a reduction of salt intake and an increase in flavonoid intake.
- the flavonoid composition of the present invention is easy to use and is suitable for both household and industrial use.
- the present invention is directed to the use of flavonoids as flavouring substances.
- the flavonoid flavouring may be used in food industry, in restaurants as well as in household cooking.
- the preferred use comprises use as a substitute for salt in food.
- the flavonoid flavouring of the present invention may be used in the food industry in ready-made foods, in bakery products, in snacks, beverages, etc. Since the flavonoids are only marginally affected by normal cooking temperatures, the flavonoids may be included into the food before cooking. If the flavonoids are to be sprinkled on the surface of foods, it may be desirable to add the flavonoids after the cooking since the flavonoid flavouring composition may be coloured dark by the heating process. In an especially preferred use of the present invention the flavonoids are sprinkled on potato chips after the deep frying procedure as a substitute for all or part of the salt normally used. In another preferred embodiment, at least a part of the salt used in baking bread is replaced by flavonoid flavouring.
- the preferred flavonoids are selected from flavonoids of onion, tea and apple, and an especially preferred mixture comprises a powdered spice containing onion powder, green or black tea extract, apple powder and mustard powder with the rest being made up of an edible carrier such as di- or tricalcium phosphate and/or silicon dioxide.
- the flavonoid powder preparation developed according to the invention is classified as a Functional Food or a Functional Spice and it can be used as a general flavouring substance. It is especially well suited for flavouring foods, but it may also be used to flavor beverages, snacks, etc.
- the preferred embodiment according to the invention comprises a mixture of flavonoids contained in onion powder, green tea extract and apple powder together with mustard powder.
- this seasoning does not necessarily contain any table salt at all, it has a taste which resembles that of a mild aroma salt.
- a specific benefit of the invention is obtained when the seasoning according to the invention is used to at least partly replace salt in the cooking of food. This makes it possible to reduce the amount of salt in the food without a reduction of the salty taste, thus providing a significant health benefit.
- Magnesium is known activator of Na-K-ATP:ase, which provides the energy for the sodium-potassium pump. Thus, lack of magnesium may impair the pumping of sodium out from the cell and potassium into the cell.
- the flavouring composition is used in combination with an agent for reducing adverse effects of table salt, such as a product described in EP0377119, wherein the active agents are potassium chloride, which provides important potassium, magnesium sulphate to compensate for deficiencies in the usual diet, lysine hydrochloride releasing hydrogen ions, citric acid, glutamic acid and ascorbic acid to release hydrogen ions on one hand and, on the other, to prevent alkalosis, since potassium and magnesium salts have an alkalizing effect.
- a suitable agent for reducing adverse effects of table salt according to the present invention should contain potassium, magnesium and weak acids, preferably it contains:
- Potassium chloride 40-85 %, preferably 55-75 %, and more preferably 60-70 %
- Magnesium sulphate 15-45 %, preferably 20-40 %, more preferably 25-35 %
- Weak acids 0.1-5 %, preferably 0.2-3 %, more preferably 0.5-2 %.
- suitable weak acids contain lysine hydrochloride, citric acid, ascorbic acid and glutamic acid.
- the weak acids can be used in combination or separately.
- the composition can further comprise potato flour, magnesium stearate or milk powder as a binding agent.
- a daily use of the flavonoid seasoning in normal cooking at home, in restaurants and/or in ready-made foods will ensure that the population will get a sufficient intake of flavonoids with their normal diet. This is believed to reduce the likelihood of coronary heart diseases and to decrease the mortality from myocardial infarction.
- the flavonoid seasoning may be portioned according to each person's taste. Since flavonoids do not decompose at heating, cooking of the food does not cause a problem.
- seasoning according to the invention may be used for example:
- flavouring lacking salt as such as a flavouring lacking salt
- flavouring including about 25% salt
- the beneficial effect of the seasoning according to the invention on health is based on the flavonoids, especially a combination of flavonoids from apple, onion and tea, which the product contains.
- the natural protective agents are in the right proportion to each other and the product so maximizes the flavonoid-protection.
- the proportions of the flavonoids may be varied according to the taste and need of the users. For instance, in a district where green tea is drunk in large amounts, the preferred seasoning may comprise less of the green tea extract and more of one or the other flavonoid ingredients. However, it has been found to be especially beneficial to mix onion powder and green tea extract in fairly equal amounts with about half that amount of apple powder.
- the seasoning according to the invention may also contain other components, such as other vegetable components containing flavonoids and components having other properties, such as special flavouring properties not natural to the flavonoids in question.
- the seasoning according to the invention is preferably mixed with edible carrier or filler compounds which are easily powdered and which add body to the seasoning.
- Such carriers are preferably inert compounds such as calcium phosphate and/or silica.
- the seasoning may also be produced in liquid or paste form and added to other seasonings such as mustard or soya sauce.
- the flavonoid composition may be used as such to be included as a flavouring and/or salt substitute into ready-made foods, bread, snacks, etc.
- the flavonoid composition has been found to have an antioxidant property which also is useful in the food industry.
- the compositions of the seasoning powder were the following :
- Typical dosage of seasoning is 1.0 - 1.5 % by weight of the food product.
- Saltyness no saltyness/light /normal saltyness
- Texture bad/acceptable/good
- the evaluators marked their opinion of the product's intensity of asked property on the 150 mm line segment.
- the line segment was anchored from it's ends and from the middle by the terms that described the studied property. Maximum for each property was 15 points and minimum 0.
- Meatballs (3 different kinds) were used as sample material.
- Saltyness The closest to "normal saltyness” was evaluated sample FIa. The closest to “no saltyness” was evaluated sample light.
- Flavor Sample FIa was evaluated as the best. Sample light was evaluated as the worst. Almost same points got sample normal.
- the flavonoid composition of the invention is a product that has a potential to help in loosing excessive body weight and lower elevated blood glucose among its multiple health promoting effects, in particular on metabolic factors.
- the flavonoid composition of the invention contains flavonoids naturally present in fruits and vegetables, including among a series of polyphenols known as catechins, which consist mainly of epigallocatechin gallate (EGCG), epicatechin gallage and gallocatechin gallate.
- the flavonoids result in a highly significant increase in breath -hydrogen concentrations, which indicate appreciable carbohydrate malabsorption.
- a comparison of hydrogen excretion after the carbohydratecontaining meal with that after the nonabsorbable disaccharide lactulose suggested that the tea extract induced malabsorption of 25% of the carbohydrate.
- flavonoids can be effectively used for preventing obesity as they decrease absorption of carbohydrates, such as sugar.
- composition of the invention is the first flavonoid product with proven effect against the oxidation of human DNA and human LDL -cholesterol.
- Oxidative stress is one of the main mechanisms through which metabolic abnormalities will cause tissue damage.
- the daily dose of the flavonoid composition of the invention being about 25-50mg per day will be sufficient in order to provide a sufficient daily dose of flavonoids, that will significantly counterbalance multiple perturbations of metabolic abnormalities, such as obesity, glucose intolerance, dyslipidaemia and insulin resistance.
- composition of the invention has a proven effect against the oxidation of human DNA and human LDL —cholesterol and it can be used to prevent atherosclerosis and / or cancer in humans.
- compositions of the flavouring compositions according to the invention are shown.
- the composition of the invention is here named as Flavomare and it may contain also a mixture named Antisalt.
- the details of the Antisalt powder are given below.
- composition of Antisalt powder is Composition of Antisalt powder
- composition Antisalt powder Green Tea powder Apple powder Onion powder The dosage is 1.0 - 1.5 %.
- Flavomare Industrial contains mustard ground for avoiding/reducing the
- bitterness in cases bitterness is to be avoided.
- Composition 1
- composition 2 Composition 3 :
- Flavomare RM 80 is discoloured, ("white”), and can be used in ready meals, (e.g. sweet juices), and in products, where viscosity and turbidity are not important.
- composition normal onion profile Composition, low onion profile
- the dosage is 1.0 -1.5 %.
- Flavomare B has very little onion to avoid the strong onion flavour, ("Low onion profile”). This suits well for bakery products.
- the dosage without potato fibre is 0.5 %, with potato fibre 0.8 %.
- This Flavomare is in liquid form and is suitable for all foodstuff especially those where the viscosity and turbidity are important factors (beverage, ready meals, confectionery e.g.). It can be used in general in dairy products and where the spices must be injected with brine, (cook hams, bacons, etc). This Flavomare can be made according to the flavour profile wished by changing the amount of onion.
- the dosage is 0.10 - 0.15 %.
- T Base 60 Green Tea
- Onion concentrated 4.00 %
- the dosage is 0.10 - 0.15 %
- This Flavomare is in "instand powder” form and is suitable for all foodstuff especially those where the viscosity and turbidity are important factors (beverage, ready meals, confectionery e.g.). It can be used in general in dairy products and where the spices must be injected with brine, (cook hams, bacons, etc).
- T Base 6O T Base 80, 70 %, mixed with hand warm water, 30 %)
- the dosage is 1.0 - 1.5 %.
- the usual dosage of Flavomare is from 0.1 % - 1.5 %.
- the % - numbers are calculated from the weight of the ready Flavomare products. If Flavomare is used as a powder, the dosage is higher, from 0.5 % - 1.5 %.
- the liquids are needed in much smaller amounts, only from 0.10 - 1.50 %, because liquids are stronger, more concentrated, in the number of synergistic active flavonoids compared to powders.
- Flavomare powder is used without anti caking agents, e.g. potato fibre, the dosage can be reduced, ⁇ 0.8 %. In products, where hygroscopic problems can be waited, it is recommended to use non-hygroscopic apple powder.
- apple powder can be mixed with some carrier, (available in the market), to reduce more the hygroscopic characteristic of the apple powders.
- the dosage is 0.1 - 0.3 %
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20075086A FI20075086L (en) | 2007-02-07 | 2007-02-07 | Flavoring composition |
PCT/FI2008/050044 WO2008096040A1 (en) | 2007-02-07 | 2008-02-06 | Flavouring composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2124629A1 true EP2124629A1 (en) | 2009-12-02 |
EP2124629A4 EP2124629A4 (en) | 2010-03-24 |
Family
ID=37832237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08709312A Withdrawn EP2124629A4 (en) | 2007-02-07 | 2008-02-06 | Flavouring composition |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2124629A4 (en) |
FI (1) | FI20075086L (en) |
WO (1) | WO2008096040A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9629384B2 (en) | 2005-09-14 | 2017-04-25 | S & P Ingredient Development, Llc | Low sodium salt composition |
US8802181B2 (en) | 2006-10-05 | 2014-08-12 | S & P Ingredient Development, Llc | Low sodium salt composition |
EP2474238A1 (en) * | 2011-01-10 | 2012-07-11 | PM-International AG | Food supplement preparation with an active ingredient mixture |
EP2747583B1 (en) * | 2011-08-25 | 2018-12-26 | Working Bugs, LLC | An improved sodium-free salt substitute |
ES2524870B2 (en) * | 2013-06-12 | 2015-06-30 | Universidad De Burgos | Seasoning of vegetable origin with preservative properties, salt substitute, and procedure for obtaining it |
US9247762B1 (en) | 2014-09-09 | 2016-02-02 | S & P Ingredient Development, Llc | Salt substitute with plant tissue carrier |
CN111093391A (en) | 2017-09-18 | 2020-05-01 | S&P 配料研发有限公司 | Low sodium salt substitute containing potassium chloride |
CA3215777A1 (en) * | 2021-03-31 | 2022-10-06 | Almendra Pte. Ltd. | Methods and compositions for improved taste quality |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI885662A (en) * | 1988-12-07 | 1990-06-08 | Selako Oy | AEMNE FOER MINSKNING AV BORDSALTETS SKADLIGA VERKAN. |
DE69736132T2 (en) * | 1996-10-31 | 2007-01-11 | Slk Foundation | AROMATIC COMPOSITION, MANUFACTURE AND USE THEREOF |
JPH10146164A (en) * | 1996-11-14 | 1998-06-02 | Kazuyoshi Higure | Curry-flavored food for sprinkling |
BG101686A (en) * | 1997-06-26 | 1998-12-30 | Анка ГОСПОДИНОВА | Concentrated extract for seasoning of vegetable sauces |
US5902626A (en) * | 1997-10-07 | 1999-05-11 | Kraft Foods, Inc. | Herb and/or spice blends having improved dispersibility and hydration |
FI973929A (en) * | 1997-10-10 | 1999-04-11 | Itara H K Ab Oy | WOF inhibitor |
JP2000060477A (en) * | 1998-08-24 | 2000-02-29 | Q P Corp | Mustard paste keeping flavor component |
JP2001086945A (en) * | 1999-07-19 | 2001-04-03 | Kano Shiyoujiyuan:Kk | Bitterness-masked food and method for masking bitterness |
FI20000004A0 (en) * | 2000-01-03 | 2000-01-03 | Slk Foundation | Flavonoidilääke ... |
JP2002027933A (en) * | 2000-07-13 | 2002-01-29 | Showa Sangyo Co Ltd | Coating material for fried food |
US7452563B2 (en) * | 2005-06-20 | 2008-11-18 | Redpoint Bio Corporation | Compositions and methods for producing flavored seasonings that contain reduced quantities of common salt |
EP1856988B1 (en) * | 2006-05-19 | 2017-09-13 | Kraft Foods R & D, Inc. | Flavonoid sugar addition products, method for manufacture and use thereof |
-
2007
- 2007-02-07 FI FI20075086A patent/FI20075086L/en not_active IP Right Cessation
-
2008
- 2008-02-06 EP EP08709312A patent/EP2124629A4/en not_active Withdrawn
- 2008-02-06 WO PCT/FI2008/050044 patent/WO2008096040A1/en active Application Filing
Non-Patent Citations (11)
Title |
---|
DATABASE TKDL "Gandhaka Mezhugu-5", XP003025979 |
DATABASE TKDL "Hingula rasayan Vidhi(2)", XP003025981 |
DATABASE TKDL "Majoon Nukra", XP003025985 |
DATABASE TKDL "Rajavarta Pisti", XP003025980 |
DATABASE TKDL AGASTHIYAR: "Malaipaambu Ennai", XP003025986 |
DATABASE TKDL D.V. PANDITARAO: "Vidangadiyogah", XP003025982 |
DATABASE TKDL KANDASAMY MUDALIAR: "Sagala Megathirkkum Ennai-1", XP003025984 |
DATABASE TKDL MOHD NAJMUL GHANI KHAN: "CHAI", XP003025063 |
DATABASE TKDL MOHD. NAJMUL GHANI KHAN: "Qahwa-e-chob Chini", XP003025983 |
DATABASE TKDL SHRI BAIDYANATH AYUVERDA BHAVAN: "Seb Ka Sarbata", XP003025315 |
See also references of WO2008096040A1 |
Also Published As
Publication number | Publication date |
---|---|
FI20075086A0 (en) | 2007-02-07 |
WO2008096040A1 (en) | 2008-08-14 |
FI20075086L (en) | 2008-08-08 |
EP2124629A4 (en) | 2010-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1855549B1 (en) | Food for preventing fatness and hyperlipemia | |
Suleria et al. | Onion: Nature protection against physiological threats | |
Lattanzio et al. | Globe artichoke: A functional food and source of nutraceutical ingredients | |
EP2124629A1 (en) | Flavouring composition | |
US20050003026A1 (en) | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them | |
JP2010522185A (en) | Composition of quercetin, myricetin and chlorogenic acid for the treatment of diabetes and metabolic disorders | |
KR20060099192A (en) | A composition for feed additive comprising plant powder or extracts containing antioxidant materials | |
EP2925160B1 (en) | Increasing the bioavailability of flavan-3-ols by polyphenols | |
Riyad et al. | Active components of squid ink and food applications | |
JP2008118933A (en) | Polyphenol composition | |
Niazi et al. | An overview: Date palm seed coffee, a functional beverage | |
Shelke et al. | Leek (Allium ampeloprasum L.) | |
Rifky et al. | Technology development to incorporate functional oil sources in yoghurt to improve functional properties | |
JP5343751B2 (en) | Food modifier | |
KR20220067561A (en) | Seasoning for seafood soup, cooking method of seafood soup and manufacturing method of the seasoning for seafood soop | |
KR101622767B1 (en) | Method for Manufacturing Sauce for spiced rib Using dietary Fiber | |
Ribeiro et al. | Flavonoids | |
Andlauer et al. | Special characteristics of non-nutrient food constituents of plants–phytochemicals introductary lecture | |
Sharma et al. | Bioavailability of nutrients and safety measurements | |
Ali et al. | Quality of guava whey beverage fortified with Moringa oleifera leaves extract | |
JP2005124540A (en) | Polyphenol composition | |
KR101261146B1 (en) | Functional Food Composition having obesity control effect and the preparation method thereof | |
Meghwar et al. | Nutritional Benefits of Bioactive Compounds from Watermelon: A Comprehensive Review | |
KR20210000779A (en) | Food composition comprising enzyme-treated grub and method for producing thereof | |
KR20060066706A (en) | Emotional tea with spicy, sweety collagen vita orange tea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090811 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100223 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/82 20060101ALI20100218BHEP Ipc: A61K 36/8962 20060101ALI20100218BHEP Ipc: A23L 1/221 20060101AFI20080827BHEP Ipc: A61K 36/31 20060101ALI20100218BHEP Ipc: A23L 1/22 20060101ALI20100218BHEP Ipc: A23L 1/225 20060101ALI20100218BHEP Ipc: A23L 1/237 20060101ALI20100218BHEP Ipc: A61K 36/73 20060101ALI20100218BHEP Ipc: A61K 36/00 20060101ALI20100218BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20100708 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110901 |